| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7700128 | TAKEDA PHARMS USA | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
Jan, 2027
(3 years from now) | |
| US8071130 | TAKEDA PHARMS USA | Solid preparation |
Jun, 2028
(4 years from now) | |
Duetact is owned by Takeda Pharms Usa.
Duetact contains Glimepiride; Pioglitazone Hydrochloride.
Duetact has a total of 2 drug patents out of which 0 drug patents have expired.
Duetact was authorised for market use on 28 July, 2006.
Duetact is available in tablet;oral dosage forms.
The generics of Duetact are possible to be released after 08 June, 2028.
Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2006
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of DUETACT before it's drug patent expiration?
More Information on Dosage
DUETACT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic